Insmed (INSM): The Revenue Beat Is Real. The Earnings Beat Is The Share Price.

Insmed Incorporated (INSM) Q2 2026 — Revenue $425.5M UP 296% vs a ~$393M bar. BRINSUPRI $309.2M in launch quarter four, UP 49% sequentially. GAAP EPS -$0.06 vs a -$0.69 bar - but 88% of that result is a $99.8M NON-CASH gain on an earnout settled in Insmed's own shares. Ex-mark EPS is -$0.52, a 17-cent beat. FY26 BRINSUPRI guidance RAISED to $1.25-$1.40B from 'at least $1B'. Stock +32.0% to $130.73. Insmed reported a net loss of six cents a share against a sixty-nine cent bar. Inside operating expenses sits a $99.8M non-cash GAIN on an earnout the 10-Q says is settled in Insmed's OWN shares. INSM fell 34.8% during the quarter - so the earnout got cheaper, and that is the beat. Strip it out and EPS is -$0.52: a 17-cent beat, not 63. The revenue beat IS real, and it is why the stock is up 32%. But at $130.73 the price already assumes the company's entire >$14B peak-sales ambition. THE CALL: AVOID (3/5, A REAL LAUNCH AT A PRICE THAT NEEDS EVERYTHING) — base-case value ~$91.0 vs ~$130.73 today. KEY METRICS: - CALL: AVOID 3/5, fair value ~$91 vs the $130.73 tape (-30%) - and 43% BELOW the Street's $161 LOW target. Panel: 35 analysts, 33 Buy / 1 Hold / 1 Sell, $199.82 average (+53%). Base $91: risk-adjusted peak revenue $9.9B in 2034 (BRINSUPRI $6.0B, ARIKAYCE $0.9B, TPIP $2.5B against a >$6B claim), FCF at 26% of sales, 10.5% discount, 2.5% terminal, +$264M net cash, 225.0M shares. Bull $150, bear $32. Backwards: $130.73 needs ~$14.3B of peak revenue. - THE 63-CENT EPS BEAT IS 88% NON-CASH. GAAP EPS printed -$0.06 against a -$0.69 bar, but total operating expenses of $427.034M include a NEGATIVE $99.760M 'change in fair value of contingent consideration liabilities'. Add it back: operating loss -$101.3M not -$1.5M, net loss -$113.0M, EPS -$0.52. The real comparable beat is 17 cents. And it reverses - at $130.73 that same earnout is worth ~$182.3M against $149.2M, a ~$33M Q3 charge. - WHY: THE EARNOUT IS SETTLED IN INSMED'S OWN SHARES. 10-Q Note 3 - the Aug-2021 Motus Biosciences / AlgaeneX earnout is up to 4,610,838 + 368,867 = 4,979,705 shares, 'settled in shares of the Company's common stock. As such, there is no discount rate applied', at a 28% weighted-average probability. 4,979,705 x 28% x $106.62 (the 6/30/26 close) = $148.7M; the filing says $149.2M. INSM fell 34.8% in the quarter. That fall IS the gain. - THE REVENUE BEAT IS REAL. Product revenue $425.486M against ~$393M expected, +296% YoY. BRINSUPRI $309.2M in launch quarter four, +49% sequentially against a ~$285M whisper (US $308.6M, international $0.6M). ARIKAYCE $116.3M, +8% - but US ARIKAYCE only +2%. Gross margin 84.2% from 73.9%. FY26 BRINSUPRI guidance RAISED to $1.25-$1.40B from 'at least $1B'; ARIKAYCE reiterated $450-470M. The 8-K was accepted 7:00am ET - a BMO print. - THE LEVERAGE IS REAL, THE PRICE IS NOT. Ex-mark operating loss -$101.3M against -$312.9M; six-month operating cash burn -$311.6M from -$467.7M while revenue tripled; we model a ~-$22M Q4 operating loss. Cash and securities $1,160M against $896M of obligations = +$264M net. But EV $28.3B is 24.9x TTM revenue, 15.8x the 2026 guide and 2.0x the company's own >$14B peak claim - $6B of which is TPIP, with 4 Phase 3s and zero readouts. - PRIMARY SOURCES (Insmed, SEC CIK 0001104506): 8-K accession 0001140361-26-031502, Ex-99.1, accepted 2026-08-06 07:00:41 ET; 10-Q accession 0001104506-26-000041, accepted 06:59:58 ET. Quarterly revenue from SEC XBRL companyconcept. What to watch: UP: a positive PALM-PAH or PALM-ILD Phase 3 readout, BRINSUPRI clearing $400M in a single quarter, or a Japanese approval with real pricing. BEAR: BRINSUPRI sequential growth under 15%, a large equity raise into this 32% move, or a US ARIKAYCE line that keeps printing 2% growth while international carries it. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.